End-Stage Renal Disease (ESRD) Market
Report ID: SQMIG35J2054
Report ID: SQMIG35J2054
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35J2054 |
Region:
Global |
Published Date: November, 2025
Pages:
219
|Tables:
61
|Figures:
75
Global End-Stage Renal Disease Market size was valued at USD 126.76 Billion in 2024 and is poised to grow from USD 143.37 Billion in 2025 to USD 383.84 Billion by 2033, at a CAGR of 13.1% during the forecast period (2026–2033).
The increasing number of individuals suffering from kidney failure and the introduction of advanced medical devices, such as low-maintenance dialysis equipment and artificial kidneys, are key drivers of this market. Chronic Kidney Disease (CKD) is a major cause of kidney failure, often resulting from conditions that lead to reduced kidney function. CKD can gradually develop over time and eventually progress to ESRD, also known as kidney failure. Factors such as hypertension, diabetes, smoking, and the aging population contribute to the development of ESRD, with diabetes being the most common cause and hypertension being the second-most frequent cause. Treatment options for ESRD/CKD include kidney transplantation or dialysis to sustain life. CKD has a high incidence rate globally, with approximately 10% of the global population suffering from the condition, leading to millions of deaths each year. The geriatric population in developing countries, such as China and India, is particularly affected. The number of patients requiring kidney transplants or dialysis is increasing at a rate of 5-7% annually. The prevalence of CKD is higher in women than men, and the rising number of individuals with hypertension and diabetes further contributes to the growth of the market. Diabetes is the primary cause of advanced kidney disease, followed by hypertension, affecting approximately 1 billion individuals worldwide. Baxter, a prominent company in this market, has announced strategic initiatives to enhance operational effectiveness and innovation, including spinning out their renal care and acute treatments global business units into a separate organization.
Regions like Africa, China, the Rest of Asia Pacific, the U.S., Taiwan, Japan, Germany, France, and Belgium have observed a high prevalence of ESRD in recent years. In the U.S., around 80 million people, or 1 in 3 adults, are at risk of CKD, making it the ninth leading cause of death. Developing countries like China and India are projected to witness an increase in cases of renal failure, particularly among the elderly population. The market growth is further supported by technological advancements in the treatment of renal failure. For example, the approval of human clinical trials for the Wearable Artificial Kidney 2.0 by the U.S. FDA in 2014 showcases the development of innovative blood purification technologies for kidney failure patients. The presence of numerous hospitals and a well-developed healthcare infrastructure in the U.S. also contributes to market growth. With a significant number of hospital admissions for acute kidney injury (AKI), there is a growing demand for dialysis and transplantation. Additionally, the number of dialysis clinics and treatment centers is increasing, with approximately 7,500 dialysis clinics currently operating in the U.S.
US End-Stage Renal Disease (ESRD) Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2026-2033
Global Market Size
USD 112.08 billion
Largest Segment
Dialysis
Fastest Growth
Dialysis
Growth Rate
13.1% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global End-Stage Renal Disease (ESRD) Market is segmented by treatment, diagnosis, end use and region. Based on treatment, the market is segmented into transplant and dialysis. Based on diagnosis, the market is segmented into blood test, urine test, imaging test and others. Based on end use, the market is segmented into hospitals, dialysis centers and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
By treatment, the market can be segmented into dialysis, kidney and transplantation. Dialysis represents the dominating segment in the ESRD market. Dialysis is the primary treatment method for patients with end-stage renal disease. It can be further divided into hemodialysis and peritoneal dialysis. Hemodialysis involves filtering waste products and excess fluids from the blood using a dialyzer machine, while peritoneal dialysis utilizes the peritoneum as a natural filter.
Kidney transplantation represents the fastest-growing segment in the ESRD market. It involves surgically replacing a diseased kidney with a healthy kidney from a living or deceased donor. This treatment option offers several advantages over long-term dialysis, such as improved quality of life, reduced treatment burden, and better long-term outcomes.
By end-user, the market can be segmented into hospitals and clinics, and home care settings. Hospitals and Clinics play a crucial role in the treatment and management of ESRD. They serve as primary care settings where patients receive comprehensive medical services, including dialysis treatments and kidney transplantation procedures. Hospitals and Clinics are equipped with specialized dialysis units, operation theaters, and intensive care facilities, allowing for comprehensive care of ESRD patients.
Home Care Settings represent the fastest growing segment in the ESRD market. It involves providing ESRD treatments and services, such as dialysis, in the comfort and convenience of patients' homes. Home dialysis allows patients to receive treatment in the familiar environment of their own homes, providing greater comfort and convenience. It enables them to have more control over their treatment schedule and reduces the need for frequent hospital visits.
To get detailed segments analysis, Request a Free Sample Report
The United States is a dominating region in the global end-stage renal disease (ESRD) market. It has a well-developed healthcare infrastructure and a significant number of hospitals, including community hospitals and federal government hospitals. The United States also has a large number of dialysis clinics, approximately 7,500 currently, catering to the increasing prevalence of ESRD. The country witnesses a high incidence of CKD and ESRD, with around 80 million people, or 1 in 3 American adults, at risk of CKD. This makes CKD the ninth leading cause of death in the United States. The presence of advanced medical technologies, research and development activities, and favorable reimbursement policies contribute to the dominance of the United States in the ESRD market.
Asia Pacific is the fastest growing region in the global end-stage renal disease market. Developing countries in this region, such as China and India, have witnessed a significant increase in the prevalence of ESRD. The geriatric population in these countries is particularly affected, leading to a rising number of patients requiring kidney transplants or dialysis. The increasing incidence of hypertension and diabetes, along with lifestyle changes, contribute to the growing burden of CKD in the Asia Pacific region. Additionally, advancements in healthcare infrastructure, technological innovations, and increasing awareness about kidney diseases and treatment options are driving the market growth in this region. The presence of a large population base and improving healthcare facilities create opportunities for market expansion and investment in the Asia Pacific region.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing prevalence of chronic kidney disease (CKD)
Limited availability and accessibility of treatment options
Request Free Customization of this report to help us to meet your business objectives.
The global end-stage renal disease (ESRD) market is characterized by the presence of several companies striving to develop innovative treatment solutions. These companies focus on research and development activities to introduce technologically advanced products in the market. Additionally, strategic initiatives such as partnerships, collaborations, and acquisitions are commonly observed in the industry. The competitive environment is driven by the pursuit of enhancing operational effectiveness, accelerating innovation, and improving patient outcomes. Market players aim to gain a competitive edge by offering comprehensive solutions and expanding their geographical presence.
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our global end-stage renal disease (ESRD) market analysis, the market is witnessing significant growth due to the increasing number of patients suffering from kidney failure and the introduction of advanced medical technologies. Chronic kidney disease (CKD), often caused by conditions like hypertension and diabetes, leads to ESRD, driving the demand for kidney transplants and dialysis treatments. The United States dominates the market with its well-developed healthcare infrastructure and numerous hospitals and dialysis clinics. Asia Pacific emerges as the fastest growing region, fueled by the rising prevalence of ESRD in countries like China and India. The market is also influenced by trends like the adoption of home-based dialysis treatments and technological advancements.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 126.76 Billion |
| Market size value in 2033 | USD 383.84 Billion |
| Growth Rate | 13.1% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the End-Stage Renal Disease (ESRD) Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the End-Stage Renal Disease (ESRD) Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the End-Stage Renal Disease (ESRD) Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the End-Stage Renal Disease (ESRD) Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global End-Stage Renal Disease USD 126.76 Billion in 2024 Market size was valued at USD 143.37 Billion in 2025 and is poised to grow from USD 383.84 Billion by 2033 to 13.1%, growing at a CAGR of (2026–2033) during the forecast period (2025-2032).
The global end-stage renal disease (ESRD) market is characterized by the presence of several companies striving to develop innovative treatment solutions. These companies focus on research and development activities to introduce technologically advanced products in the market. Additionally, strategic initiatives such as partnerships, collaborations, and acquisitions are commonly observed in the industry. The competitive environment is driven by the pursuit of enhancing operational effectiveness, accelerating innovation, and improving patient outcomes. Market players aim to gain a competitive edge by offering comprehensive solutions and expanding their geographical presence. 'AngioDynamics, Inc. (US) ', 'Asahi Kasei Medical Co., Ltd. (Japan) ', 'B. Braun Melsungen AG (Germany) ', 'Baxter International, Inc. (US) ', 'Becton Dickinson and Company (US) ', 'Cantel Medical (US) ', 'DaVita Inc. (US) ', 'Fresenius Medical Care AG & Co. KGaA (Germany) ', 'JMS Co., Ltd. (Japan) ', 'Medtronic Plc (Ireland) ', 'Nikkiso Co., Ltd. (Japan) ', 'Nipro Corporation (Japan) ', 'Teleflex Incorporated (US) ', 'Toray Industries Inc. (Japan) ', 'U.S. Renal Care, Inc. (US) ', 'Pfizer Inc. (US) ', 'AstraZeneca (UK) ', 'Bristol-Myers Squibb Company (US) ', 'Dr. Reddy's Laboratories Ltd. (India) ', 'Endo International plc (Ireland)'
One significant driver in the global end-stage renal disease market is the increasing prevalence of chronic kidney disease (CKD), particularly driven by conditions such as hypertension and diabetes. With a high number of individuals worldwide being affected by these chronic diseases, the risk of developing CKD and eventually progressing to ESRD rises. This escalating patient population necessitates the demand for effective treatment options, including kidney transplantation or dialysis, thereby propelling the growth of the market.
One key market trend in the global end-stage renal disease (ESRD) market is the increasing adoption of home-based dialysis treatments. This trend is driven by the desire to improve patient convenience, reduce healthcare costs, and enhance patient outcomes. Home dialysis therapies, such as peritoneal dialysis and home hemodialysis, offer greater flexibility, independence, and the ability to receive treatment in the comfort of one's own home. This shift towards home-based dialysis is being supported by advancements in technology, improved training programs, and favorable reimbursement policies, thus driving the growth of the market.
The United States is a dominating region in the global end-stage renal disease (ESRD) market. It has a well-developed healthcare infrastructure and a significant number of hospitals, including community hospitals and federal government hospitals. The United States also has a large number of dialysis clinics, approximately 7,500 currently, catering to the increasing prevalence of ESRD. The country witnesses a high incidence of CKD and ESRD, with around 80 million people, or 1 in 3 American adults, at risk of CKD. This makes CKD the ninth leading cause of death in the United States. The presence of advanced medical technologies, research and development activities, and favorable reimbursement policies contribute to the dominance of the United States in the ESRD market.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
